Owkin Doses First Patient in Phase I Trial of OKN4395 for Solid Tumors
Owkin Announces First Patient Dosed in Phase I Trial of OKN4395 for Solid Tumors Owkin, a leader in AI-driven biotech, has reached a significant milestone in its innovative journey with the dosing of the first patient in the Phase I…